In this study we aimed to further investigate the efficacy of selvigaltin, the most clinically advanced galectin-3 oral small molecule inhibitor, in an HFD-induced MetS rabbit model to provide insight into predicted pharmacologically active doses in human. Here, LGALS3 is linked to metabolic syndrome.